📰 Clinical Development Program News
Page 5 - Clinical Development Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development Program. Real-time updates on events, politics, business and more.
June 25, 2023
Data from SURMOUNT-2 presented at ADA 2023 build on results from the SURMOUNT-1 trial, with results detailing the weight loss achieved with tirzepatide in people with type 2 diabetes and overweight or obesity.
June 24, 2023
/PRNewswire/ -- Detailed results from SURMOUNT-2, a phase 3 clinical trial evaluating the efficacy and safety of Eli Lilly and Companys (NYSE: LLY)...
June 5, 2023
Daiichi Sankyo and AstraZeneca’s ENHERTU showed an objective response rate of 37.1% in the overall population of the DESTINY-PanTumor02 phase 2 trial ENHERTU is the first therapy to show... | June 5, 2023
May 27, 2023
VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like ...
May 26, 2023
FN Media Group Presents USA News Group News Commentary VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American
May 26, 2023
VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like ...
May 26, 2023
/PRNewswire/ -- USA News Group - The worlds biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...
May 16, 2023
Eight presentations at ASCO and EHA 2023 Annual Meetings showcase continued leadership in CAR-T cell therapy research for patients with multiple myeloma across various clinical settings First... | May 16, 2023
May 9, 2023
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today announced that the Companys product portfolio of FDA-approved brands delivered combined revenues of $9.2 million during the... | May 9, 2023
May 1, 2023
/PRNewswire/ -- New secondary analysis from Eli Lilly and Companys (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who...